4.6 Article

The Inactivation of Arx in Pancreatic α-Cells Triggers Their Neogenesis and Conversion into Functional β-Like Cells

Journal

PLOS GENETICS
Volume 9, Issue 10, Pages -

Publisher

PUBLIC LIBRARY SCIENCE
DOI: 10.1371/journal.pgen.1003934

Keywords

-

Funding

  1. Juvenile Diabetes Research foundation [17-2011-16, 2-2010-567, 26-2008-639, 17-2013-426]
  2. INSERM AVENIR program
  3. INSERM
  4. European Research Council [StG-2011-281265]
  5. FMR [DRC20091217179]
  6. ANR/BMBF [GENO 105 01/01KU0906]
  7. Investments for the Future LABEX SIGNALIFE [ANR-11-LABX-0028-01]
  8. Max-Planck Society
  9. Club Isatis
  10. Fondation Generale de Sante
  11. Foundation Schlumberger pour l'Education et la Recherche
  12. DON Foundation
  13. Fund for Scientific Research-Flanders

Ask authors/readers for more resources

Recently, it was demonstrated that pancreatic new-born glucagon-producing cells can regenerate and convert into insulinproducing beta-like cells through the ectopic expression of a single gene, Pax4. Here, combining conditional loss-of-function and lineage tracing approaches, we show that the selective inhibition of the Arx gene in alpha-cells is sufficient to promote the conversion of adult alpha-cells into beta-like cells at any age. Interestingly, this conversion induces the continuous mobilization of duct-lining precursor cells to adopt an endocrine cell fate, the glucagon(+) cells thereby generated being subsequently converted into beta-like cells upon Arx inhibition. Of interest, through the generation and analysis of Arx and Pax4 conditional double-mutants, we provide evidence that Pax4 is dispensable for these regeneration processes, indicating that Arx represents the main trigger of alpha-cell-mediated beta-like cell neogenesis. Importantly, the loss of Arx in alpha-cells is sufficient to regenerate a functional beta-cell mass and thereby reverse diabetes following toxin-induced beta-cell depletion. Our data therefore suggest that strategies aiming at inhibiting the expression of Arx, or its molecular targets/co-factors, may pave new avenues for the treatment of diabetes.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available